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Abstracts / Osteoarthritis and Cartilage 28 (2020) S86eS527S106Methods: Primary chondrocytes were isolated from the joint cartilages
of OA patients undergoing total knee arthroplasty (grade 4, mean age:
68 years, BMI: 31.4 ± 6.0 kg/m2). Cells were treated with different
concentrations (ZeyEX®) for 24 h. The alterations in cell proliferation
(MTT), adhesion profile (RTCA-iCELLigence System), reactive oxygen
species generation (ROS), lipid hydroperoxide levels (LPO), HNE-protein
adduct levels (HNE), AGE-protein adduct levels (AGE), 3-nitrotyrosine
levels (3-NT) and inflammatory progenitors ICE/caspase-1, IL-1b, IL-6
and TNF-a levels (ELISA) were determined. Moreoever, toll-like rece-
petor-4 (TLR-4) and Receptor for AGE (RAGE) levels were quantified by
Western blot analysis.
Results: Cell viability of OACs were significantly increased at lower
concentrations (1-10 nM) of ZeyEX® and seemed to be non-toxic at
nanomolar concentrations (Figure 1A). In addition to that, adherence
capacity of OACs were dramatically increased at 1 nM concentration
(Figure 1B). ZeyEX® treatment reduced the ROS, AGE and HNE levels
slightly (p<0.05-0.01) in concominant with the drastic reduction in LPO
and 3-NT levels (p<0.01-0.001) (Figure 1C). Treatment with ZeyEX® (10
nM- 10 mM) not only downregulated the inflammatory progenitor ICE/
caspase-1 levels, but also IL-1b and IL-6 were decreased significantly in
all concentrations (p<0.001) (Figure 1D). However, Tnf- a levels were
dramatically increased only at 100 nM concentration (p<0.05)
(Figure 1D). Moreover, RAGE and TLR-4 levels were decreased tre-
mendously after ZeyEX® (>100 nM) treatment (Figure 1E,1F) (p<0.05 to
p<0.001).
Conclusions: Our results suggest that lower concentrations of ZeyEX®
ameliorates oxidative-nitrosative stress mediated pro-inflammatory
cytokine release along with the induction of proliferation and adher-
ence capacity in human primary chondrocytes, in vitro.
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PROTEOGLYCAN 4 EXPRESSION BY SUPERFICIAL ZONE CHOND-
ROCYTES IS REGULATED IN PART BY JNK AND P38 IN VITRO
E. Delve, M. Di Scipio, R. Kandel. Lunenfeld Tanenbaum Res. Inst., Mount
Sinai Hosp., Inst. of Biomaterials and BioMed. Engineering, Univ. of
Toronto, Toronto, ON, Canada
Purpose: Osteoarthritis (OA) is a degenerative disease that affects joint
homeostasis leading to cartilage degeneration. Inflammatory media-
tors, including interleukin-1 (IL-1) and tumor necrosis factor-a (TNF-a),
are key factors in this catabolic process that are known to activate the
mitogen-activated protein kinases (MAPKs) and have been shown to
play a central role in mediating this degradative response by OA
chondrocytes. However, these studies typically use chondrocytes from
full-thickness cartilage. A study by Rosenzweig et al. showed that the
temporal and spatial expression of phosphorylated MAPKs in response
to cartilage injury was zone-specific, and observed a chondroprotective
effect of activation of the MAPK jun amino-terminal kinase (JNK) and
p38 mitogen-activated protein kinase (p38) in the superficial zone (SZ).
The purpose of this study was to investigate the role of JNK and p38 in
regulating key aspects of the SZ phenotype including cell morphology,
actin polymerization status, expression of the chondroprotective SZ
molecule proteoglycan 4 (PRG4), and localization of yes-associated
protein and transcriptional co-activator with PDZ-binding motif, whichwe have previously shown to regulate PRG4 expression in SZ chon-
drocytes (SZC).
Methods: Bovine chondrocytes were isolated from the SZ of the met-
acarpo-phalangeal joint of calves aged 6-9 months by sequential
digestion of the tissue in 0.5% protease (45 minutes) followed by 0.1%
collagenase (14-17 hours). SZC were seeded in monolayer in high glu-
cose DMEM supplemented with ITS, 100nM dexamethasone, 40mg/mL
proline, 100mM pyruvate, 100mg/mL ascorbic acid. After 24 hours of
culture, SZC were treated with either SP600125 (JNK inhibitor (JKNi);
10mM) or SB203580 (p38 inhibitor (p38i); 5mM) and the effects on the
SZ phenotype (cell shape, actin polymerization status, and PRG4
expression, YAP/TAZ localization) were assessed after 24 hours of
treatment. Cell shape was evaluated by measuring cell circularity and
area using Image J software analysis. Actin polymerization status was
assessed by visualizing globular and filamentous actin by confocal
microscopy and determining the ratio of globular to filamentous actin,
which was extracted by differential triton extraction and separated by
SDS-PAGE. PRG4 mRNA levels was determined by RT-PCR. YAP/TAZ
localization was assessed by fractionating the cellular cytoplasmic and
nuclear components (NE-PER Nuclear and Cytoplasmic Extraction Kit;
ThermoFisher Scientific) and evaluating them by SDS-PAGE followed by
western blot. Experiments were repeated with SZC from 3 independent
cell isolations. Statistical analysis was performed using Student’s T-test
with significance assigned as p<0.05.
Results: SZC at 24 hours maintain their phenotype as demonstrated by
their spindle cell shape and secretion of PRG4. To determine whether
JNKi and p38i affect chondrocyte morphology and actin organization,
SZC were treated with JNKi and p38i and cell shape and actin poly-
merization status was assessed. Treatment with JNKi did not sig-
nificantly affect cell area (N¼3; p¼0.43) but resulted in an increase in
cell circularity (N¼3; p¼0.047). No changes in actin organization were
observed with confocal microscopy, and no significant changes in the
G-/F-actin ratio were observed (N¼4; p¼0.5) with JNKi treatment.
Treatment with p38i did not affect cell area (N¼3; p¼0.13) or circularity
(N¼3; p¼0.91). Similarly, no changes in actin organization were
observed with confocal microscopy, and no significant changes in the
G-/F-actin ratio (N¼4; p¼0.49) were observed with p38i treatment.
Despite no change in actin polymerization status with treatment, a
decrease in nuclear TAZ was observed with JNKi (N¼5; p¼0.03) and
p38i (N¼4; p¼0.009) treatment. No change in levels of cytoplasmic YAP
was observed with JNKi treatment; however, treatment with the p38i
resulted in an increase in cytoplasmic YAP (N¼4; p¼0.02). PRG4 mRNA
levels decreased with JNKi (N¼3; p<0.0001) and p38i (N¼3; p<0.001)
treatment.
Conclusions: The data suggests that JNK and p38 regulates TAZ nuclear
localization and PRG4 expression without affecting actin cytoskeleton
status. Regulation of the SZ phenotype is complex and likely results
from the convergence of several major regulatory pathways. While
actin polymerization and nuclear localization of YAP/TAZ have been
shown to regulate PRG4 expression, JNK and p38 also appear to regulate
PRG4 expression and YAP/TAZ localization; however it has yet to be
determined whether JNK and p38 act downstream of actin polymer-
ization or independent of actin polymerization. Understanding the
regulatory mechanisms governing the SZ phenotype and the expression
of the chondroprotective molecule PRG4 may provide insight into
therapeutic treatments to delay the onset or progression of OA.
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A MULTICOMPONENT MEDICATION PROMOTES CHONDROGENESIS
AND REDUCES MMP-13 IN PRIMARY ARTICULAR CHONDROCYTES
FROM KNEE OSTEOARTHRITIS PATIENTS IN VITRO
C. Sanchez 1, K. Hemmer 2, N. Kr€ommelbein 2, B. Seilheimer 2,
J.-E. Dubuc 3, C. Antoine 4, Y. Henrotin 1. 1Univ. of Liege, Liege, Belgium;
2Heel, Baden-Baden, Germany; 3Orthopedic Dept., UCL, Bruxelles,
Belgium; 4Artialis S.A., Liege, Belgium
Purpose: HE-1100 is a multicomponent medicinal product. Initial pre-
clinical data potentially suggest a preventive effect on cartilage degra-
dation. This study aims to understand the mode of action of HE-1100 on
OA chondrocytes in vitro.
Methods: Primary chondrocytes were obtained from 10 knee osteo-
arthritis (OA) patients undergoing knee replacement surgery. The cul-
tures were treated with 20% (v/v) HE-1100 or placebo. Samples were
collected for subsequent RNA extraction using standard methods. The
reads were generated with Illumina NextSeq5000 sequencer and
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transcriptome. Differential expression analysis between HE-1100 and
placebo was made in R using the DESeq2 package to identify the dif-
ferentially expressed genes in the OA-associated regulatory pathways.
The protein production of the selected genes was quantified by ELISA in
10 independent human OA chondrocytes cultures.
Results: According to the DESeq2 analysis, HE-1100 significantly
modified the expression of 13 genes in OA chondrocytes by at least 10%
with an adjusted p-value < 0.05 : EGR1 (þ93%), FOS (þ87%), NR4A1
(þ43%), DUSP1 (þ18%), ZFP36 (þ18%), ZFP36L1 (þ14%), NFKBIZ (þ16%)
and CYR61 (þ14%) were upregulated and ATF7IP (-10%), TXNIP (-11%),
C10orf10 (-12%), CLEC3A (-12%) and MMP13 (-18%) were down-
regulated after 24h HE-1100 treatment. HE-1100 significantly increased
(2.3 fold þ/-1.2 after 24h, p¼0.0444 and 2.3-fold þ/-1.0 after 72h,
p¼0.0239) the CYR61 protein production by human OA chondrocytes.
After 72h, HE-1100 slightly but not significantly increased aggrecan
production by 14 ± 19 % (p¼0.1117) and significantly increased type II
collagen pro-peptide production by 27 ± 20 % (p¼0.0147). For both time
points CYR61 production by OA chondrocytes was positively and sig-
nificantly correlated with aggrecan (r¼0.66, p¼0.0004) and type II
collagen pro-peptide (r¼0.64, p¼0.0008) production. In alginate beads
culture, pro-MMP-13 was significantly decreased by HE-1100 treated
cultures from day 7 to day 14 (from -16 to -25 %, p<0.05) and from day
17 to 21 (-22 %, p¼0.0331) in comparison to controls.
Conclusions: HE-1100 significantly modified the expression of DUSP1,
C10orf10, ZFP36/L1 and CLEC3A, which are pathwaymediators involved
in MMP-13 expression and activation. Further, long-term (28 days)
treatment with HE-1100 significantly reduced the production of pro-
MMP-13, the inactive precursor of the metalloproteinase MMP-13
involved in type II collagen degradation. HE-1100 also promoted
extracellular matrix formation probably through CYR61 production, a
growth factor well correlated with type II collagen and aggrecan pro-
duction.
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AN IN VITRO CHONDROGENIC DIFFERENTIATION MODEL USING
KS483 MOUSE MESENCHYMAL PROGENITOR CELL LINE
K.M. Fagerlund 1, N. Habilainen-Kirillov 1, C.W. Lowik 2, A. Chan 3,
J.M. Halleen 1. 1 Pharmatest Services, Turku, Finland; 2Dept. of Radiology,
Leiden Univ. Med. Ctr., Leiden, Netherlands; 3 Percuros BV, Leiden,
Netherlands
Purpose: KS483 cells are multipotent mouse mesenchymal progenitor
cells that are able to differentiate into chondrocytes, adipocytes and
osteoblasts and are a well-characterized model for the study of osteo-
blast differentiation and bone formation. We have studied the use of
KS483 cell line in an in vitro model of chondrogenic differentiation.
Methods: The cells were cultured in three-dimensional (3D) pellet
culture system in serum-free differentiation medium in the presence
and absence of BMP-6 for 17-28 days. The pellets were cultured in 96-
well plates and the medium was changed in 2-3 day intervals. The
pellets were embedded in paraffin, sectioned and stained for Safranin O
and Alcain blue for assessment of sulfated glycosaminoglycan (sGAG)
content, and processed for immunohistochemistry to visualize type II
collagen. For biochemical analysis, the pellets were digested with pro-
teinase K and assayed for sGAG at days 17, 24 and 28. Type II collagen
carboxyterminal propeptide (CP-II) was determined in the culture
medium collected at day 17.
Results: Based on histological analysis, BMP-6 showed concentration-
dependent stimulatory effects on chondrogenic differentiation,
increased sGAG content of the pellets, and increased CP-II released into
the culture medium.
Conclusions: These results suggest that the KS483 cell line can be used
for setting up an in vitro model for studying chondrogenic differ-
entiation and for identifying novel compounds with anabolic effects on
chondrogenesis. As these cells can rapidly proliferate, they provide an
unlimited source of easily expanded progenitor cells for conducting
large number of replicates and studies.
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GENERATION OF AN INDUCIBLE TISSUE SPECIFIC DIO2 OVER-
EXPRESSION MOUSE
F.M. Cornelis 1, S. Monteagudo 1, L. Storms 1, J.J. Haigh 2, R.J. Lories 1. 1KU
LEUVEN, LEUVEN, Belgium; 2Univ. OF MANITOBA, WINNIPEG, MB, CanadaPurpose: Osteoarthritis (OA) is one of the most common chronic
musculoskeletal disorders, for which the current therapeutic strategies
are limited. Progressive damage to the articular cartilage and bone leads
to pain and loss of joint function. The development of OA is very
complex, due to the activation of several signaling pathways in the
different tissues composing the joint, and is influenced by both genetic
and environmental risk factors. GWAS studies identified an association
between OA and the DIO2 gene. DIO2 is an enzyme belonging to the
iodothyronine deiodinase family. It intracellularly activates thyroid
hormone by converting T4 to T3. OA is characterized by the loss of the
stable phenotype of chondrocytes and progression towards hyper-
trophy. Our hypothesis is that DIO2 needs to be reduced in aged carti-
lage, to maintain the stable phenotype of the articular chondrocytes.
Indeed, we previously documented that Dio2 knockout mice are pro-
tected against cartilage damage in a treadmill-running OA model and
this was also reflected in a specific gene expression profile, marking
either a protective effect in Dio2 knockout or an OA-triggering effect in
wild-type cartilage.
Methods: We have generated a new transgenic mouse model, over-
expressing DIO2, under the control of an inducible Aggrecan promoter
using the Cre-recombinase system. We have introduced the DIO2 cDNA
in the ROSA locus, preceded by a floxed STOP-cassette. We first deter-
mined the functionality of different tagged and modified versions of the
DIO2 protein using a Thyroid-responsive luciferase reporter assay. Next,
the necessary targeting vector was constructed, using the Gateway
recombination system. After homologous recombination in ES cells,
correctly recombined ES cell colonies were identified using PCR and
Southern Blot analysis; and these were used in blastocyst injection
experiments to obtain transgenic mice. This mouse was intercrossed
with an Acan-Cre mouse, driving Tamoxifen-dependent expression of
Cre recombinase in fully differentiated cartilage chondrocytes (gen-
erating ‘DIO2 KI’ mice). A transcriptome analysis of the articular carti-
lage of DIO2 KI mice was performed. RNA was isolated from articular
cartilage of the tibial plateau of the knee and used in an RNA sequencing
study to compare gene expressionwith cartilage from normal wild-type
C57Bl/6 mice (Illumina NextSeq500).
Results: Dio2 KI mice are currently being challenged in a spontaneous
OA model of ageing and in a treadmill-running OA model. Articular
cartilage of DIO2 KI mice was analyzed in an RNA sequencing tran-
scriptomics analysis. Our initial pathway analysis of these data suggests
a dysregulation of lipid metabolism due to DIO2 gain-of-function.
Conclusions: Our preliminary results demonstrate that this mouse is a
useful model to study the development of OA, and confirm the
involvement of DIO2 herein.
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TNF ALPHA-STIMULATED GENE 6 (TSG6) IS CHONDROPROTECTIVE IN
VIVO BUT OVEREXPRESSION CANNOT COMPENSATE FOR LOSS OF
FGF2
L. Zhu, S. Lympany, J.M. Zarebska, A. Burleigh, T.L. Vincent. Kennedy Inst.
of Rheumatology, Univ. of Oxford, Oxford, United Kingdom
Purpose: TNF alpha stimulated gene 6 (TSG6) is expressed in response
to tissue injury and has purported tissue-protective and anti-inflam-
matory effects. High levels of TSG6 have been detected in the synovial
fluid of patients with OA and following acute knee injury. Our published
work shows that TSG6 is regulated after joint destabilisation in mice, in
a highly mechanosensitive and fibroblast growth factor 2 (FGF2)-
dependent fashion. As FGF2-/- mice develop accelerated OA, and injury-
induced FGF2-dependent genes such as Timp1 and inhibin were
downregulated in TSG-6-/- mouse joints, we speculated that the chon-
droprotective role of FGF2 may be mediated through TSG6. We asked
whether overexpressing TSG-6 could reduce the severity of OA in wild
type or FGF2-/- mice.
Methods: OA was induced by cutting the medial menisco-tibial liga-
ment (DMM) in 10-12 week old male and female TSG6-/-, TSG6tg, FGF2-/-
mice with their respective controls (C57BL/6 and Balb/c), and male
FGF2-/-;TSG6tgþ/þ or FGF2-/-;TSG6tg-/- mice. Focal cartilage injury was
also performed in male and female TSG6tg mice. 8 and 12 weeks post-
surgery, joints were sectioned and the severity of cartilage degradation
was assessed according to a modified OARSI score. FGF2 levels were
measured in cartilage injury conditioned medium from FGF2-/-, Balb/c,
TSG-6tgþ/þ, TSG-6tg-/þ, TSG-6tg-/- hips by V-PLEX bFGF kit from Meso
Scale Discovery (MSD, Rockville, MD).
